Luc Heraudet, Charlotte Domblides, Amaury Daste, Félix Lefort, Jean-Christophe Bernhard, Alain Ravaud, Marine Gross-Goupil
Expert opinion on drug safety 2020 JulThe safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer. In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either in the more recent adjuvant setting after nephrectomy or in the metastatic setting, with a focus on new data from the CARMENA and SURTIME trials. In particular, the aim was to determine the specificity of toxicity in the adjuvant setting. In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized. Consequently, as described mainly in the metastatic setting, management of the adverse effects of sunitinib remains critical.
Luc Heraudet, Charlotte Domblides, Amaury Daste, Félix Lefort, Jean-Christophe Bernhard, Alain Ravaud, Marine Gross-Goupil. Safety of sunitinib in patients with renal cell carcinoma following nephrectomy. Expert opinion on drug safety. 2020 Jul;19(7):799-806
PMID: 32521179
View Full Text